(d) if so, what is the justification for sanctioning the proposal of a multinational company whose activi ties of overcharging of prices, over-production without permission and unauthorised installation of plant and machinery are within the know ledge of Government?

THE MINISTER OF CHEMICALS AND FERTILIZERS AND INDUSTRY AND COMPANY AFFAIRS (SHRI VEERENDRA PATIL): (a) The Technical team conducted on-the-spot I inspection of plant and machinery of ' M/s. Glaxo Labs, in May, 1984.

(b) The letters of intent held by Glaxo for Cephalexin Griseofulvin are from the basic stage. The technology content is not required to be assessed under the 1978 Drug Policy as the letters of intent were issued after Glaxo ceased to be a FERA company;

(c) *Onhr* Indian Drugs & Pharma-ceauticals Ltd. hold an Industrial Licence for the manufacture of Griseofulvin but have not produced the drug on commercial scale because of lack of suitable technology. No public sector undertaking is licensed to produce Cephalexin.

(d) Glaxo Labs, were issued letters of intent for the above two bulk drugs as per the provisions/ parameters of this Drug Policy, 1978.

Industrial Licence of Multinational Drug Manufacturers

1771 (MOLANA) ASRARUL HAQ: Will the Minister of CHEMI CALS AND FERTILIZERS be pleased to St:

ire the proposals sub-Industrial licence by Glaxo. Roche, Hoechst, Abbot and Wyeth after the announcement of Drug Policy 1978 upto , 31st March, 1985 indicating the names of bulk drugs, capacity applied for and the stage of manufacture, in each case;

(b) what are the drugs for which proposals were rejected; and the drugs for which proposals were recommended by Government and letters of intents/industrial licences issued, indicating the capacity approved and stage of manufacture in each case;

(c) whether it is a fact that the process of all the drugs cleared for permission have been identified as high technology;

(d) if so, whether identification was done by a group of experts or adviser-drugs only; and

(e) what are the names of the other organised units licensed to produce these drugs, indicating their licensed and installed capacity of each?

THE MINISTER OF CHEMICALS AND FERTILIZERS AND INDUSTRY AND COMPANY AFFAIRS (SHRI VEERENDRA PATIL); (a) and (b) Details of proposals submitted for industrial licence by M/s. Glaxo, Roche, Hoechst, Abbott and Wyeth after the announcement of Drug Policy, 1978 upto 31st March, 1985 together with other details are given in the enclosed Statement.

(c) and <*d)* Processes of all the bulk drugs cleared for licensing in respect of FERA companies have been identified as high technology either by the High Level Committee o'r as per the criterian laid down by the High Level Committee.

(e) Details *viz.* name and address of the undertakings, items of manufacture', capacity in respect of which industrial approvals have been issued are being published regularly by the Indian Investment Centre in their monthly news letter. Copies of this publication are available in the Parliament Library.

Statement

S. No.	Name of the Company	Item of manufacture applied	Whether Rejected approved	Capacity approved
1	2	3	4	5
1	M/s Hoechst India Ltd.	(i) Furosemic (ii) Glybenclamide (iii) Avil Maleate	(S.E.) Rejected	–
2	M/s Hoechst India Ltd.	Canine Distmeper and virus Hepatitis	Approved	5 lacs doses (within the overall licensed capacity of FMD vaccine)
3	M/s Glaxo . . .	Betamethasone	Approved	300 Kgs-425 Kgs (SE).
4	M/s Roche Products .	Sulphamethoxazole (SE)	Rejected	–
5	M/s Roche Produts .	Flourouracil	Rejeteed	–
6	M/s Hoechst India Ltd.	Pernylamineetate	Rejected	–
7	M/s Hoechst India Ltd.	Haemaccel	Approved	1.5 to 4.5 lakh Ltrs.
8	M/s Hoechst India Ltd.	Fenrendazole	Approved	3500 Kgs.
9	M/s Hoechst India Ltd.	Baralgan Ketone	Rejeeted	–
10	M/s Roche Products .	Sulphadoixne	Rejeeted	–
11	M/s Roche Products .	Ornidazole	Rejeeted	–
12	M/s Glaxo Labs. . .	(i) Sotalol Hcl*	Approved	(i) 2,2325 kgs.
		(ii) Laevimisol*		(ii) 1,380 kgs.
		(iii) Norethisterone*		(iii) 270 kgs.
		(iv) Pentazocine Hcl./ Lactate*		(iv) 1,375 kgs.
		(v) Ibuprofen*		(v) 1,740 kgs.
		(vi) Furalozidone	Rejected	
		(vii) Diphenoixlate Hcl*		
		(viii) Chlorpheniramine***		
		(ix) Dequalinium Chloride**		
13.	M/s Roche Products .	Isopropyl Antipyrine	Rejected	–
14.	M/s Hoechst India Ltd.	Beta-pressin Substance (Penbutol)	Rejected	–
15.	M/s Hoechst India Ltd.	Antagosan (Aprotinine)	Approved	10,000 Ltrs.
1 .	M/s Wyeth Labs.	Hydrocortisone & Esters	Rejeted	–

1	2	3	4	5
17	M/s Glaxo Labs.	(i) Corticosteroids	Rejected	
		(ii) Beclomethasone Dipropionate		
18	M/s Hoechst India Ltd.	Buclosamide	Approved	1,070 Kgs.
19	M/s Glaxo Labs	(i) Beclomethason Dipropionate	Rejected	—
		(ii) Clobetasol Propionate		
		(iii) Clobetasole Butyrate		
20	M/s Hoechst India Ltd.	Ethacricine Lactate	Approved	20 Tons
21	M/s Glaxo Labs.	Griseofulvin	Approved	20 tons
22	M/s Roche Products .	Clarprofen	Rejected	—
23	M/s Roche Products .	Orinidazole	Rejected	—
24	M/s Roche Products .	Bromazepam	Rejected	—
25	M/s Hoechst India Ltd.	Reagents for Diagnostics .	Approved	2,40,000 Kits.
26	M/s Glaxo Labs. .	Cephalexin	Approved	15 Tons
27	M/s Wyeth Labs. .	Androstenolone	Approved	200 kgs.
28	M/s Wyeth Labs.	(i) Norgestrel and its Isomers	Approved	(i) 200 kgs.
		(ii) Betamethasone and its esters/salts		(ii) 150 kgs.
29	M/s Hoechst India Ltd.	Pentoxytylline (Trental)	Approved	10 Tonnes
30	M/s Hoechst India Ltd.	Betapressin	Rejected	—
31	M/s Hoechst India Ltd.	Betrafen	Rejected	—
32	M/s Hoechst India Ltd.	Cornecaine	Rejected	—
33	M/s Glaxo Labs. .	Ranitidine	Rejected	—
34	M/s Hoechst India Ltd.	Reagents for Diagnostics	Rejected	—

(These proposal do not include applications for 100% export).

Study on mark up

1772. SHRI MOLANA ASRARUL HAQ: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) when was the study with regard to observing of mark up on formulations conducted under DPCO 1970 or DPCO 1979.

(b) whether it is a fact that such a study is long overdue and also that no study of mark up was made either by the working groups or by the National Drugs and Pharmaceutical Development Council;

(c) whether Government propose to hold such a study, and if not, on what basis it would recommend mark up on the formulations as a result of the review of 1978 Drug Policy; and

(d) whether there is any proposal to set up a group to go into the question of mark up on formulations and if so, by when such a group is likely to be constituted?

THE MINISTER OF CHEMICALS AND FERTILIZERS AND INDUSTRY AND COMPANY AFFATRS (SHRI VEERENDRA PATIL): (a) After due consideration, mark-ups